BioRestorative Therapies, Inc. · NASDAQ:BRTX
BioRestorative Therapies — Investor Presentation (January 2024)
24 slides from BioRestorative Therapies's investor presentation, January 2024
Slide 1: BioRestorative Therapies
Rectorate therapies ——=pf Nasdaq of Nasdaq Company aN 40 Marcus Drive, Melville, 11747 NY 1 www.biorestorative.com
Slide 2: Forward Looking Statement
FORWARD LOOKING STATEMENT STATEMENTS IN THIS PRESENTATION, INCLUDING THE INFORMATION SET FORTH AS TO THE FUTURE FINANCIAL OR OPERATING PERFORMANCE OF BIORESTORATIVE THERAPIES, INC. (THE “COMPANY”) THAT ARE NOT CURRENT OR HISTORICAL FACTUAL STATEMENTS MAY CONSTITUTE “FORWARD LOOKING” INFORMATION WITH
Slide 3: Leadership
LEADERSHIP LANCE ALSTODT ROBERT KRISTAL FRANCISCO SILVA BOB PACCASASSI Chairman & CEO Chief Financial Officer Vice President of R&D Vice President of Quality Lance leads BRTX’s mission to Robert has a versatile Francisco has over 20 years of Robert has over 25 years of improve the lives of patients
Slide 4: Fully Integrated Regenerative Medicine Company
FULLY INTEGRATED REGENERATIVE MEDICINE COMPANY Preclinical Clinical Commercial BioCosmetics ThermoStem BRTX-100 Cell based Tech Bone Marrow Derived ECM, Exosomes, Brown Adipose Mesenchymal Stem Derived Stem Cells Growth Factors and Cells hPL 4
Slide 5: Commercial Cosmetic Products
BIORESTORATIVE THERAPIES INC-COMMERCIAL COSMETIC PRODUCTS Key Features of Cosmetics and Hair Growth Biologics Products • Global Cosmetic market $63 • cGMP ISO 7 Certified Facility • Umbilical cord derived billion and growing • Molecular Biology Expertise • Highly enriched & potent • Global injectabl
Slide 6: Clinical / Preclinical Programs
Clinical / Preclinical Programs Preclinical Phase 1 Phase 2 Phase 3 Spine • Lumbar Autologous • Cervical • Thoracic Musculoskeletal System • Hips/Knees • Extremities • Avascular Zones Metabolic • Type 2 Diabetes • Obesity Allogeneic • PCOS Brown Adipose Stem Cells • ARDS • Long Hauler Covid Gene Mod
Slide 7: Chronic Lumbar Disc Disease Program – Phase 2
CHRONIC LUMBAR DISC DISEASE PROGRAM – PHASE 2 Lead investigational therapeutic product Autologous (patient’s own) cell-based biologic Hypoxic (low oxygen) cultured, bone marrow-derived Single intradiscal injection – anticipated 30 minute in-office procedure DISC/SPINE Prior human data prov
Slide 8: Market Opportunity – BRTX-100
MARKET OPPORTUNITY – BRTX 100 258 MILLION American adult population 64.5 MILLION American adults with chronic lower back pain prevalence 32 MILLION American adults with diagnosed and treated disc degeneration 15 MILLION Americans have pain caused by a protruding or injured disc 2.5 MILLION Invasive
Slide 9: Standard of Care: Clinical and Economic Problem
STANDARD OF CARE: CLINICAL AND ECONOMIC PROBLEM CONSERVATIVE TREATMENTS SURGICAL TREATMENTS OFTEN RECURRENT WITH RE-OP RATES OFTEN 10-20% ORAL MEDICATION TREATMENT/OPIOIDS SIMPLE ELEGANT SOLUTION SPINAL FUSION SURGERY INTRODUCE HYPOXIC CULTURED $1,000 - $2,000 Annually AUTOLOGOUS MSCs $110,000 1, 5
Slide 10: Logistical/Clinical Process
LOGISTICAL/CLINICAL PROCESS Shipping 3 Shipping 1 Cryoport 5 Cryoport . Intradiscal delivery Bone marrow and BRTX-100® blood collected from Manufactured & of BRTX-100® subject QC released Sample shipped at BRTX-100® shipped ambient to frozen to clinical BioRestorative site Therapies Clinical Site 2
Slide 11: Cleared DSMB June 2023
CLEARED DSMB June 2023 • Unanimous approval by the DSMB to continue trial without changes • BRTX-100 is safe and well tolerated • All 4 subjects successfully dosed with either 40 mil hMSCs or placebo • First time 40 million cells injected in a human subject • 3:1 randomization • No Significant Adver
Slide 12: Positive Human Data
POSITIVE HUMAN DATA Human data from studies of therapies similar to brtx-100 show reduced pain, increased function, and an absence of significant safety issues with a durable response. 12
Slide 13: Trial Design
TRIAL DESIGN FDA Cleared IND 17275: Phase 2 Randomized, Controlled Study Design in Patients with CLDD Study Design and Patient Population Study includes 99 subjects (2:1 product to placebo) 40.000.000 cells/dose Included subjects will have only one symptomatic diseased disc Primary efficacy
Slide 14: Competitive Landscape Key Differentiating Factors
COMPETITIVE LANDSCAPE KEY DIFFERENTIATING FACTORS KEY ATTRIBUTES BRTX-100 ADVANTAGES: Normoxic cultured – Autologous cells means low to no risk of rejection, Hypoxic cultured – in low with normal oxygen greater safety profile (introduction of viral/genetic), oxygen environment (5%) environment (~2
Slide 15: BioRestorative Therapy Programs
BIORESTORATIVE THERAPY PROGRAMS Metabolic Program ThermoStem Program “Off the shelf” allogeneic cell-based therapy targeted to treat obesity, Type 2 diabetes and metabolic disorders using brown fat stem cells Brown fat has been shown to regulate metabolic homeostasis in the body Large librar
Slide 16: Metabolic Program Highlights
METABOLIC PROGRAM HIGHLIGHTS • First human stem cell derived BAT transfer White Fat • Creation of first human 3D engineered artificial brown adipose tissue construct (aBAT) • Successful delivery of 3D aBAT construct in mouse model Beige Fat • Transplantation of aBAT lowered blood glucose levels • Tr
Slide 17: Metabolic Program Clinical Pathway
METABOLIC PROGRAM CLINICAL PATHWAY • Expect filing a Drug Master File (“DMF”) with the FDA to facilitate licensing opportunities around Thermostem • Scheduling Pre-IND (Investigational New Drug) meeting with FDA to discuss first-in-man fast-track regulatory pathways • Upon FDA approval commence Phas
Slide 18: Intellectual Property
INTELLECTUAL PROPERTY PROGRAM: PROGRAM: DISC/SPINE METABOLIC (THERMOSTEM) PATENT TITLES PATENT TITLES • Methods and Compositions to facilitate repair • Brown Fat Compositions and Methods of avascular tissue • Human Brown Adipose Derived Stem Cells and Uses • Surgical Methods and Compositions to • No
Slide 19: 2023 Accomplishments
2023 ACCOMPLISHMENTS Expanded Thermostem patent portfolio in US and Japan Two Notice of Allowances Completed 4 patient Safety Run-in component for Phase 2 Announced a filing and execution of an ATM Announced Northwell Healthcare Partnership – Largest Healthcare System in the Northeast Cl
Slide 20: Scientific Advisory Board
SCIENTIFIC ADVISORY BOARD Dr. Marasco, is a principal faculty member of Harvard Stem Cell Institute as well as a Professor in the Department WAYNE MARASCO, MD, PhD of Cancer Immunology & AIDS at the Dana-Farber Cancer Institute and a Professor of Medicine at Harvard Chairman of SAB Medical School. J
Slide 21: Company Highlights
COMPANY HIGHLIGHTS cGMP ISO-7 Certified Clean room Disruptive Platform Technologies in Cellular Therapy Strong Preliminary Data Indicative of Positive Trial Outcomes Active Phase 2 Trial in Spine Addressing Multi-Billion Dollar Markets with Unmet Needs Opportunity for Key Strategic Partn
Slide 22: Financial Summary
FINANCIAL SUMMARY Current Capitalization Shares Basic Shares Outstanding 4,706,000 Cash 12.2 MILLION Debt $0 Data as Q3 filing 22
Slide 23: BioRestorative Upcoming Milestones
BIORESTORATIVE UPCOMING MILESTONES Platform Stage Situation Overview Skin regeneration, Tissue derived facial application • Regenerative Cosmetic & Aesthetic treatment to rejuvenate Exosome product /hair growth skin and grow hair Degenerative Disc BRTX-100 Disease (DDD) • Anticipate providing update
Slide 24: Biorestorative Therapies Inc.
Biorestorative Therapies Inc. • Address: 40 Markus Drive, Melville, NY 11747 Suite 1 • Phone: 631-760-8100 • Website: www.biorestorative.com 24
BioRestorative Therapies — Investor Presentation (January 2024) on 6ix